Risk Factors Associated with Adverse Outcomes after Ablative Surgery for Lymphedema.

Journal of reconstructive microsurgery 2023 Vol.39(3) p. 214-220

Kuruvilla AS, Shroyer ALW, Li X, Yang J, Mulay SR, Agha SM, Bellis RM, Kohli HK, Tannous HJ, Krajewski A

관련 도메인

Abstract

[BACKGROUND]  Postmastectomy breast cancer lymphedema poses an important health threat. Historically, physical therapy was the exclusive treatment option. More recently, lymphedema surgery has revolutionized care. As a first-in-kind, multicenter report, the postmastectomy breast cancer patients' risk factors associated with postlymphedema ablative surgical outcomes were documented.

[METHODS]  Using the New York Statewide Planning and Research Cooperative System database from 2010 to 2018, multivariable models identified the postmastectomy breast cancer lymphedema surgical patients' characteristics associated with major adverse outcomes and mortality.

[RESULTS]  Of 65,543 postmastectomy breast cancer patients, 1,052 lymphedema surgical procedures were performed including 393 (37.4%) direct excisions and 659 (63.6%) liposuctions. Direct excision and liposuction surgical patients had median ages of 58 and 52 years, respectfully ( < 0.001). Although a 30-day operative mortality was rare (0.3%, all direct excisions), major adverse outcomes occurred in 154 patients (28.5% direct excision; 6.4% liposuction;  < 0.0001). Multivariable clinical outcomes model identified that patients with higher Elixhauser's score, renal disease, emergent admissions, and direct excision surgery had higher incidences of adverse outcomes (all  < 0.01). For those patients with 30-day readmissions ( = 60), they were more likely to have undergone direct excision versus liposuction (12.5 vs. 1.7%;  < 0.0001). The important risk factors predictive of future cellulitis/lymphangitis development included diabetes mellitus, Medicaid insurance, renal disease, prior cellulitis/lymphangitis, chronic obstructive pulmonary disease (COPD), and chronic steroid use (all  < 0.01).

[CONCLUSION]  Lymphedema surgery carries a favorable risk profile, but better understanding the "high-risk" patients is critical. As this new era of lymphedema surgery progresses, evaluating the characteristics for adverse postoperative outcomes is an important step in our evolution of knowledge.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 4
시술 liposuction 지방흡입 dict 3
합병증 cellulitis 감염 dict 2
해부 pulmonary scispacy 1
합병증 Lymphedema scispacy 1
합병증 renal disease scispacy 1
약물 steroid C0038317
Steroids
scispacy 1
약물 [BACKGROUND] scispacy 1
약물 65,543 scispacy 1
질환 Lymphedema C0024236
Lymphedema
scispacy 1
질환 breast cancer lymphedema C4277512
Breast Cancer Lymphedema
scispacy 1
질환 breast cancer C0006142
Malignant neoplasm of breast
scispacy 1
질환 renal disease C0022658
Kidney Diseases
scispacy 1
질환 diabetes mellitus C0011849
Diabetes Mellitus
scispacy 1
질환 chronic obstructive pulmonary disease C0024117
Chronic Obstructive Airway Disease
scispacy 1
질환 COPD → chronic obstructive pulmonary disease C0024117
Chronic Obstructive Airway Disease
scispacy 1
질환 postmastectomy breast cancer patients scispacy 1
질환 postmastectomy breast cancer lymphedema scispacy 1
질환 breast cancer patients scispacy 1
기타 patients scispacy 1

MeSH Terms

Humans; Female; Breast Neoplasms; Breast Cancer Lymphedema; Mastectomy; Lymphangitis; Cellulitis; Lymphedema; Risk Factors

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문